Literature DB >> 19933799

Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function.

Akihiro Tanaka1, Tetsuya Aiba, Takashi Otsuka, Katsuya Suemaru, Tatsuya Nishimiya, Tomoyoshi Inoue, Mitsuharu Murase, Yuji Kurosaki, Hiroaki Araki.   

Abstract

We determined the population pharmacokinetics of vancomycin (VAN) using the glomerular filtration rate (GFR) estimated from the serum cystatin C concentration. We examined the predictive performance of the trough serum VAN concentration for determination of the initial dose by using a new model for the analysis of the population pharmacokinetic parameters. Data for 86 patients were used to estimate the values of the population pharmacokinetic parameters. Analysis with a nonlinear mixed-effects modeling program was done by using a one-compartment model. Data for 78 patients were used to evaluate the predictive performance of the new model for the analysis of population pharmacokinetic parameters. The estimated GFR values determined by using Hoek's formula correlated linearly with VAN clearance (VAN clearance [ml/min]=0.825xGFR). The mean volume of distribution was 0.864 (liters/kg). The interindividual variability of VAN clearance was 19.8%. The accuracy of the prediction determined by use of the new model was statistically better than that determined by use of the Japanese nomogram-based model because the 95% confidence interval (-3.45 to -1.38) of the difference in each value of the mean absolute error (-2.41) did not include 0. Use of the serum cystatin C concentration as a marker of renal function for prediction of serum VAN concentrations may be useful.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933799      PMCID: PMC2812172          DOI: 10.1128/AAC.00661-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects.

Authors:  T A Golper; H M Noonan; L Elzinga; D Gilbert; R Brummett; J L Anderson; W M Bennett
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

3.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Population pharmacokinetics of vancomycin in Japanese adult patients.

Authors:  M Yasuhara; T Iga; H Zenda; K Okumura; T Oguma; Y Yano; R Hori
Journal:  Ther Drug Monit       Date:  1998-04       Impact factor: 3.681

5.  Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations.

Authors:  K A Rodvold; R D Pryka; M Garrison; J C Rotschafer
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

6.  Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.

Authors:  Jesús Hermida; J Carlos Tutor
Journal:  Ther Drug Monit       Date:  2006-06       Impact factor: 3.681

7.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Monitoring vancomycin therapy.

Authors:  M J Rybak; S C Boike
Journal:  Drug Intell Clin Pharm       Date:  1986-10

9.  Nephrotoxicity of vancomycin, alone and with an aminoglycoside.

Authors:  M J Rybak; L M Albrecht; S C Boike; P H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

10.  Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C.

Authors:  E Wasén; R Isoaho; K Mattila; T Vahlberg; S-L Kivelä; K Irjala
Journal:  J Intern Med       Date:  2004-07       Impact factor: 8.989

View more
  18 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

Review 2.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.

Authors:  Sepideh Elyasi; Hossein Khalili; Simin Dashti-Khavidaki; Amirhooshang Mohammadpour
Journal:  Eur J Clin Pharmacol       Date:  2012-03-13       Impact factor: 2.953

3.  Cystatin C and/or creatinine-based estimated glomerular filtration rate for prediction of vancomycin clearance in long-stay critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome (PICS): a population pharmacokinetics analysis.

Authors:  Jingjing Huang; Xiaoli Wang; Chenxia Hao; Wanhua Yang; Weixia Zhang; Jialin Liu; Hongping Qu
Journal:  Intern Emerg Med       Date:  2021-03-16       Impact factor: 3.397

4.  Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective.

Authors:  Guo Yu; Guo-Fu Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

5.  Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Wei Wu; Zheng Jiao; Rong-Fang Lin; Chang-Zhen Jiang; Pin-Fang Huang; Yi-Wei Liu; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-10-01       Impact factor: 2.953

Review 6.  Cystatin C as a potential biomarker for dosing of renally excreted drugs.

Authors:  Nguessan Aimé Brou; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

7.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

8.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients.

Authors:  Tingjie Guo; Reinier M van Hest; Luca F Roggeveen; Lucas M Fleuren; Patrick J Thoral; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Paul W G Elbers
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

9.  Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.

Authors:  Laurent Bourguignon; Yoann Cazaubon; Guillaume Debeurme; Constance Loue; Michel Ducher; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

10.  Underestimation of the calculated area under the concentration-time curve based on serum creatinine for vancomycin dosing.

Authors:  Sung Joon Jin; Ji Hyun Yoon; Bo Sook Ahn; Ji Ah Chung; Young Goo Song
Journal:  Infect Chemother       Date:  2014-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.